1-20 of 41
Deepu Madduri
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

SOR-CART-MM-001 Study: A Phase I, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Edward A. Stadtmauer, Omar Elghawy, Todd F. Roberts, Deepu Madduri, Sikander Ailawadhi, Mike Royal, Ying Yan
Journal: Blood
Blood (2023) 142 (Supplement 1): 6851.
https://doi.org/10.1182/blood-2023-178636
Published: 2023
Journal Articles

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Jens Hillengass, Adam D. Cohen, Mounzer E Agha, Michel Delforge, Tessa Kerre, Wilfried Roeloffzen, Hermann Einsele, Hartmut Goldschmidt, Katja Weisel, Marc S. Raab, Christof Scheid, Sebastien Anguille, Pieter Sonneveld, Sonja Zweegman, Jordan M. Schecter, Kevin C De Braganca, Carolyn Chang Jackson, Philip Vlummens, Helen Varsos, Christina Corsale, Deepu Madduri, Tzu-min Yeh, Pankaj Mistry, Tito Roccia, Qingxuan Song, Muhammad Akram, Octavio Costa Filho, Dong Geng, Yael C. Cohen, Niels W.C.J. Van De Donk
Journal: Blood
Blood (2023) 142 (Supplement 1): 1021.
https://doi.org/10.1182/blood-2023-178882
Published: 2023
Journal Articles

Clinical Experience with Cranial Nerve Impairment in the CARTITUDE-1, CARTITUDE-2 Cohorts A, B, and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel)

Niels W.C.J. Van De Donk, Surbhi Sidana, Jordan M. Schecter, Carolyn Chang Jackson, Nikoletta Lendvai, Kevin C De Braganca, Ana Slaughter, Carolina Lonardi, Philip Vlummens, Helen Varsos, Christina Corsale, Deepu Madduri, Shirin Jadidi, Junchen Gu, Hao Zhao, Katherine Li, Erin Lee, Loreta Marquez, Man Zhao, Tzu-min Yeh, Diana Chen, Erika Florendo, Nitin Patel, Muhammad Akram, Jaime Gellego Perez-Larraya, Paula Rodriguez Otero
Journal: Blood
Blood (2023) 142 (Supplement 1): 3501.
https://doi.org/10.1182/blood-2023-178743
Published: 2023
Journal Articles

Biomarker Correlates of Response to Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma from CARTITUDE-1, a Phase 1b/2 Open-Label Study, at the ~3 Year Follow-up

Rocio Montes de Oca, Junchen Gu, Hao Zhao, Kathy Zelinsky, Dianna Wu, Cuc Davis, Jaymala Patel, Brad Foulk, Rengasamy Boominathan, Onsay Lau, Denis Smirnov, Yi Lin, Sundar Jagannath, Adam D. Cohen, Nahor Haddish-Berhane, Jean Xu, Deepu Madduri, An-Sofie Stevens, Carolyn Chang Jackson, Jordan M. Schecter, Arnob Banerjee, Dong Geng, Jieqing Zhu, Sifan Xu, Enrique Zudaire
Journal: Blood
Blood (2023) 142 (Supplement 1): 2099.
https://doi.org/10.1182/blood-2023-182298
Published: 2023
Journal Articles

DVRd Followed By Ciltacabtagene Autoleucel Versus DVRd Followed By ASCT in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study ( EM agine/CARTITUDE-6)

Mario Boccadoro, Jesús San-Miguel, Kenshi Suzuki, Niels W.C.J. Van De Donk, Gordon Cook, Andrzej Jakubowiak, Deepu Madduri, Salma Afifi, An-Sofie Stevens, Jordan M. Schecter, William Deraedt, Steven Kuppens, Pankaj Mistry, Lida Pacaud, Erika Florendo, Annemiek Broijl, Francesca Gay, Roberto Mina, Leo Rasche, Philippe Moreau, María-Victoria Mateos, Hermann Einsele, Pieter Sonneveld
Journal: Blood
Blood (2022) 140 (Supplement 1): 4630–4632.
https://doi.org/10.1182/blood-2022-157021
Published: 2022
Journal Articles

Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Myeloma Patients Undergoing BCMA-CAR-T: An Exploratory Analysis from CARTITUDE-1

Karen Sweiss, Pritesh Patel, Janet Guo, Kyeongmin Kim, Jordan M Schecter, Christina Y Sheng, Dawei Song, Xiaoying Xu, Yaming Su, Weirong Wang, Deepu Madduri, Carolyn C Jackson, Enrique Zudaire, Tzu-min Yeh, Tito Roccia, Dong Geng, Lida Pacaud, Douglas W Sborov, Mitch A Phelps, Craig C Hofmeister
Journal: Blood
Blood (2022) 140 (Supplement 1): 4323–4324.
https://doi.org/10.1182/blood-2022-159501
Published: 2022
Journal Articles

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

Nikhil C. Munshi, Bruno Paiva, Thomas Martin, Saad Usmani, Yi Lin, Jordan M. Schecter, Carolyn C. Jackson, Deepu Madduri, Enrique Zudaire, Tzu-min Yeh, J. Blake Bartlett, Lida Pacaud, Muhammad Akram, Dong Geng, Sundar Jagannath, Adam D. Cohen, Jesús San-Miguel
Journal: Blood
Blood (2022) 140 (Supplement 1): 4652–4654.
https://doi.org/10.1182/blood-2022-159141
Published: 2022
Journal Articles

Pathogenic Germline Variants in Multiple Myeloma

Santiago Thibaud, Aaron Etra, Ryan Subaran, Zachry Soens, Scott Newman, Rong Chen, Ajai Chari, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, David T. Melnekoff, Shambavi Richard, Joshua Richter, Larysa Sanchez, Kuan-lin Huang, Alessandro Lagana, Samir Parekh, Kenan Onel
Journal: Blood
Blood (2021) 138 (Supplement 1): 399.
https://doi.org/10.1182/blood-2021-151495
Published: 2021
Journal Articles

Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature

Paula Restrepo, Sherry Bhalla, Adolfo Aleman, Violetta Leshchenko, Sarita Agte, Yogita Ghodke-Puranik, Joy Jiang, Mark M. Stevens, Deepu Madduri, Joshua Richter, Shambavi Richard, Ajai Chari, Hearn Jay Cho, Sundar Jagannath, Christopher J Walker, Yosef Landesman, Alessandro Lagana, Samir Parekh
Journal: Blood
Blood (2021) 138 (Supplement 1): 457.
https://doi.org/10.1182/blood-2021-150522
Published: 2021
Journal Articles

Anakinra Targeting Cytokine Release Syndrome Associated with Chimeric Antigen Receptor T-Cell Therapies

Sandy W. Wong, Shambavi Richard, Yi Lin, Deepu Madduri, Carolyn C. Jackson, Enrique Zudaire, Vadim Romanov, Michael Trigg, Martin Vogel, Ashraf Garrett, Lisa Hullinger, Tonia Nesheiwat, Thomas Martin, Sundar Jagannath
Journal: Blood
Blood (2021) 138 (Supplement 1): 2812.
https://doi.org/10.1182/blood-2021-150592
Published: 2021
Journal Articles

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

Thomas Martin, Saad Z. Usmani, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Deepu Madduri, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Yi Lin, Sundar Jagannath
Journal: Blood
Blood (2021) 138 (Supplement 1): 549.
https://doi.org/10.1182/blood-2021-146060
Published: 2021
Journal Articles

Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis

Andrzej Jakubowiak, Saad Z. Usmani, Jesus G. Berdeja, Mounzer Agha, Adam D Cohen, Parameswaran Hari, Jordan M. Schecter, Deepu Madduri, Tzu-Min Yeh, Yunsi Olyslager, Arnob Banerjee, Carolyn C. Jackson, Alicia Allred, Enrique Zudaire, William Deraedt, Changwei Zhou, Dong Geng, Lida Pacaud, Yi Lin, Thomas Martin, Sundar Jagannath
Journal: Blood
Blood (2021) 138 (Supplement 1): 3938.
https://doi.org/10.1182/blood-2021-146069
Published: 2021
Journal Articles

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

Deepu Madduri, MD, Jesus G. Berdeja, MD, Saad Z. Usmani, MDMBBS,MBA, Andrzej Jakubowiak, MD PhD, Mounzer Agha, MD, Adam D. Cohen, MD, A. Keith Stewart, MBChB, Parameswaran Hari, MD MRCP, Myo Htut, MD, Elizabeth O'Donnell, MD, Nikhil C. Munshi, MD, David E. Avigan, MD, Abhinav Deol, MD, Alexander M. Lesokhin, MD, Indrajeet Singh, PhD, Enrique Zudaire, PhD, Tzu-Min Yeh, Alicia J. Allred, PhD, Yunsi Olyslager, MSc, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Jordan M. Schecter, MD, Carolyn C. Jackson, MD MPH, William Deraedt, MSc, Sen Hong Zhuang, MD PhD, Jeffrey R. Infante, MD, Dong Geng, PhD, Xiaoling Wu, PhD, Marlene J. Carrasco, MD PhD MPH, Muhammad Akram, MD, Farah Hossain, PharmD, Syed Rizvi, MD, Frank Fan, MD PhD, Sundar Jagannath, MD, Yi Lin, MD PhD, Thomas Martin, III, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–25.
https://doi.org/10.1182/blood-2020-136307
Published: 2020
Journal Articles

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

Melissa Alsina, MD, Nina Shah, MD, Noopur S. Raje, MD, Sundar Jagannath, MD, Deepu Madduri, MD, Jonathan L. Kaufman, MD, David S. Siegel, MD PhD, Nikhil C. Munshi, MD, Jacalyn Rosenblatt, MD, Yi Lin, MD PhD, Andrzej Jakubowiak, MD PhD, Jagoda Jasielec, MD, Alison Timm, MS, Ashley Turka, Pingping Mao, PhD, Nathan Martin, PhD, Timothy B. Campbell, MD PhD, Kristen Hege, Hans Bitter, PhD, Fabio Petrocca, MD, Jesus G. Berdeja, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-140410
Published: 2020
Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

Yi Lin, MD PhD, Noopur S. Raje, MD, Jesus G. Berdeja, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Michaela Liedtke, MD, Jacalyn Rosenblatt, MD, Marcela V. Maus, MD PhD, Monica Massaro, MPH, Fabio Petrocca, MD, Andrea Caia, MS, Zhihong Yang, PhD, Timothy B. Campbell, MD PhD, Kristen Hege, MD, Nikhil C. Munshi, MD, James N. Kochenderfer, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-134324
Published: 2020
Journal Articles

28-Day Metronomic Therapy for Relapsed Refractory Multiple Myeloma

Tarek H Mouhieddine, MD, Julia Hieulle, Erin Moshier, MS, Josh R. Richter, MD, Hearn Jay Cho, MD PhD, Samir Parekh, MD, Ajai Chari, MD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13.
https://doi.org/10.1182/blood-2020-142210
Published: 2020
Journal Articles

Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Thomas Martin, III, MD, Yi Lin, MD PhD, Mounzer Agha, MD, Adam D. Cohen, MD, Myo Htut, MD, A. Keith Stewart, MBChB, Parameswaran Hari, MD MRCP, Jesus G. Berdeja, MD, Deepu Madduri, MD, Saad Z. Usmani, MDMBBS,MBA, Tzu-Min Yeh, Alicia J. Allred, PhD, Yunsi Olyslager, MSc, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Jordan M. Schecter, MD, Carolyn C. Jackson, MD MPH, William Deraedt, MSc, Katharine S. Gries, PhD PharmD, John Fastenau, RPh, MPH, PhD, Xiaoling Wu, PhD, Marlene J. Carrasco, MD PhD MPH, Muhammad Akram, MD, Farah Hossain, PharmD, Andrzej Jakubowiak, MD PhD, Sundar Jagannath, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-136368
Published: 2020
Journal Articles

REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Deepu Madduri, MD, Ashley Rosko, MD, Jason Brayer, PhDMD, Jeffrey Zonder, William I. Bensinger, MD, Jingjin Li, PhD, Linzhi Xu, PhD, Lieve Adriaens, PharmD, Dhruti Chokshi, BS, Weijiang Zhang, PhD, Anita Boyapati, PhD, Manish Sharma, MD, Frank Seebach, MD, L. Andres Sirulnik, MD PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Madhav V. Dhodapkar, MD, Suzanne Lentzsch, MD PhD, Dennis Cooper, MD, Sundar Jagannath, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-139192
Published: 2020
Journal Articles

Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study

Yi Lin, MD PhD, Thomas Martin, III, MD, Adam D. Cohen, MD, Andrzej Jakubowiak, MD PhD, Jagoda Jasielec, MD, Saad Z. Usmani, MDMBBS,MBA, Deepu Madduri, MD, Mounzer Agha, MD, A. Keith Stewart, MBChB, Indrajeet Singh, PhD, Enrique Zudaire, PhD, Tzu-Min Yeh, Alicia J. Allred, PhD, Yunsi Olyslager, MSc, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Jordan M. Schecter, MD, Carolyn C. Jackson, MD MPH, William Deraedt, MSc, Dong Geng, PhD, Xiaoling Wu, PhD, Marlene J. Carrasco, MD PhD MPH, Muhammad Akram, MD, Farah Hossain, PharmD, Vickie Wang, PhD, Jesus G. Berdeja, MD, Sundar Jagannath, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-136360
Published: 2020
Journal Articles

Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab

Guido Lancman, MD, Dahniel Sastow, BA, Minira Aslanova, MD, Erin Moshier, MS, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Samir Parekh, MD, Shambavi Richard, MD, Joshua Richter, MD, Larysa Sanchez, MD, Ajai Chari, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 6–7.
https://doi.org/10.1182/blood-2020-140056
Published: 2020